---
layout: default
title: Aluminum Oxide Anemone Pratensis Beryllium Cadmium
parent: 僅模型預測 (L5)
nav_order: 284
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Anemone Pratensis Beryllium Cadmium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Metallic Mixture: No Repurposing Prediction Generated

## One-Sentence Summary

This submission refers to a 16-ingredient mixture comprising toxic heavy metals (lead, cadmium, beryllium, mercuric sulfate), precious metals (gold, platinum, silver), trace elements, and botanical ingredients (Anemone pratensis, Plantago major).
The TxGNN model was **unable to generate any repurposing predictions** for this combination, and the mixture has no regulatory approval in Taiwan.
No clinical trials, literature evidence, or approved indications were identified; evaluation cannot proceed under the standard framework.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None found |
| Predicted New Indication | None — no prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (below L5 — no prediction output) |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this mixture; therefore this section cannot be completed in the standard format.

The 16-ingredient combination — aluminum oxide, anemone pratensis, beryllium, cadmium, calcium sulfide, copper, gold, lead, mercuric sulfate, molybdenum, nickel, plantago major, platinum, selenium, silver, and tin — does not correspond to any recognized single-agent drug entry in DrugBank (DrugBank ID: not found). Without a resolvable pharmacological identity, the TxGNN knowledge graph cannot anchor the compound to a node and therefore produces no candidate indications.

The mixture's composition is most consistent with a **homeopathic or anthroposophic preparation**, where these substances are used at ultra-high dilutions. Under that interpretation, the "drug" as a whole lacks a conventional mechanism of action, which explains the failure to match any DrugBank vocabulary entry and the absence of model output. Mechanism of action data (Data Gap DG002) was not retrievable, and TFDA package insert warnings (Data Gap DG001) were not obtained — both are classified as blocking or high-severity gaps.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

No formal safety data was returned by the DDI query or the TFDA package insert lookup for this specific combination. Based on established toxicological knowledge of the individual components, the following concerns are noted:

- **Lead**: Neurotoxin and nephrotoxin; WHO affirms no safe level of exposure. Causes irreversible neurodevelopmental damage.
- **Cadmium**: IARC Group 1 carcinogen; accumulates in the renal cortex and causes Itai-itai disease with chronic exposure.
- **Beryllium**: IARC Group 1 carcinogen; causes chronic beryllium disease (berylliosis), an incurable granulomatous lung disorder.
- **Mercuric Sulfate**: Mercury compound; nephrotoxin and neurotoxin with narrow toxic threshold.
- **Nickel**: IARC Group 1 carcinogen in specific compound forms; strong contact allergen.

> If this preparation is intended for homeopathic use, dilution levels (e.g., 30C, 200C) would be expected to bring elemental concentrations well below detectable limits. Confirm preparation grade and dilution before any toxicological risk assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This mixture contains established toxic heavy metals and IARC Group 1 carcinogens (lead, cadmium, beryllium, mercury), has zero regulatory approvals in Taiwan, no identifiable original indication, and produced no TxGNN repurposing output — there is no evidence basis on which to proceed.

**To proceed, the following is needed:**

- **Clarify formulation intent**: Confirm whether this is a homeopathic/anthroposophic preparation and specify dilution grade. If so, individual active substance analysis may not be applicable.
- **Resolve DrugBank identity (DG002)**: Attempt mapping of each individual component separately to obtain mechanism of action data and enable per-ingredient TxGNN runs.
- **Obtain TFDA package insert (DG001)**: Download and parse TFDA PDF for any registered warnings and contraindications applicable to the mixture.
- **Conduct toxicological risk assessment**: Heavy metal safety profile must be characterized before any clinical use discussion is possible.
- **Re-run TxGNN per active ingredient**: If the mixture cannot be mapped as a unit, run the prediction pipeline on pharmacologically active individual components (e.g., selenium, copper) that have DrugBank IDs.
- **Establish regulatory classification**: Determine whether this preparation falls under pharmaceutical, homeopathic, or dietary supplement regulation in Taiwan, as this governs the applicable evidence standard.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

